Jawad H. Butt
YOU?
Author Swipe
View article: Obesity, aldosterone, and natriuretic peptides in patients with heart failure and reduced ejection fraction
Obesity, aldosterone, and natriuretic peptides in patients with heart failure and reduced ejection fraction Open
Aims Experimental evidence suggests that adipose tissue may secrete aldosterone, and mineralocorticoid receptor antagonists (MRAs) appear to be more effective in patients with obesity. Therefore, we examined aldosterone levels according to…
View article: Temporal trends in fatal and non-fatal heart failure admissions in Denmark from 1996 to 2022: A 25-year analysis of >180.000 patients with incident heart failure
Temporal trends in fatal and non-fatal heart failure admissions in Denmark from 1996 to 2022: A 25-year analysis of >180.000 patients with incident heart failure Open
Background Over the past 25 years, the mortality risk associated with heart failure (HF) has decreased in some countries, probably due to the implementation of evidence-based therapy. However, it remains uncertain whether HF admission rate…
View article: Effect of implantable cardioverter-defibrillator in non-ischemic heart failure according to heart failure etiology: Extended follow-up of the DANISH trial
Effect of implantable cardioverter-defibrillator in non-ischemic heart failure according to heart failure etiology: Extended follow-up of the DANISH trial Open
Rates of sudden cardiovascular death (or all-cause death) did not differ across different etiologies of non-ischemic HF. HF etiology did not modify the effects of primary-prevention ICD implantation compared with usual care.
View article: Implantable Cardioverter-Defibrillator and Frailty in Non-ischemic Heart Failure With Reduced Ejection Fraction: Extended Follow-Up of the DANISH Trial
Implantable Cardioverter-Defibrillator and Frailty in Non-ischemic Heart Failure With Reduced Ejection Fraction: Extended Follow-Up of the DANISH Trial Open
Patients with frailty are often perceived to have a less favorable risk/benefit profile for pharmacological and device-based therapies. We examined the long-term effects of a primary prevention implantable cardioverter-defibrillator (ICD),…
View article: Polycystic ovarian syndrome and long-term risk of acute myocardial infarction and ischaemic stroke
Polycystic ovarian syndrome and long-term risk of acute myocardial infarction and ischaemic stroke Open
Aims Polycystic ovary syndrome (PCOS) affects 5–20% of reproductive-aged women and is linked to cardiovascular risk factors and atherosclerosis. Yet, its long-term association with atherosclerotic cardiovascular disease remains uncertain a…
View article: Atrial fibrillation and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: insights from the DANISH trial
Atrial fibrillation and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: insights from the DANISH trial Open
Aims Atrial fibrillation (AF) is associated with an increased risk of sudden cardiac death. Therefore, the effect of an implantable cardioverter-defibrillator (ICD) may be greater in patients with AF. We examined the long-term effects of p…
View article: Finerenone According to Frailty in Heart Failure
Finerenone According to Frailty in Heart Failure Open
Importance Patients with frailty are often perceived to have a less favorable benefit-risk profile for novel therapies and therefore may be less likely to receive these. Objective To examine the efficacy and safety of finerenone, compared …
View article: Mortality after transcatheter aortic valve replacement in young multimorbid patients as compared to an age-, gender- and comorbidity-matched background population
Mortality after transcatheter aortic valve replacement in young multimorbid patients as compared to an age-, gender- and comorbidity-matched background population Open
Introduction Contrary to the current guidelines patients with symptomatic severe aortic stenosis and ≤65 years of age are often referred for transcatheter aortic valve replacement (TAVR). However, the outcome after TAVR in this patient coh…
View article: Reply to ‘Further considerations on the <scp>FINEARTS</scp>‐<scp>HF</scp> trial’
Reply to ‘Further considerations on the <span>FINEARTS</span>‐<span>HF</span> trial’ Open
No abstract available.
View article: Associations of Body Mass Index on worsening of heart failure and mortality in patients with heart failure and reduced left ventricular ejection fraction: A 10-year follow-up study (A NorthStar Substudy)
Associations of Body Mass Index on worsening of heart failure and mortality in patients with heart failure and reduced left ventricular ejection fraction: A 10-year follow-up study (A NorthStar Substudy) Open
Background Obesity is common in heart failure with reduced ejection fraction (HFrEF). As anti-obesity treatments advance, understanding how body mass index (BMI) affects outcomes in HFrEF is increasingly important. Objective To examine whe…
View article: Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With Heart Failure and Reduced Ejection Fraction in PARADIGM‐HF
Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With Heart Failure and Reduced Ejection Fraction in PARADIGM‐HF Open
Background Women with heart failure (HF) ejection fraction appeared to respond more favorably to sacubitril/valsartan, compared with valsartan, than men in PARAGON‐HF (Prospective Comparison of ARNI With ARB Global Outcomes in Heart Failur…
View article: Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction according to body weight
Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction according to body weight Open
NCT00232180.
View article: Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the <scp>FINEARTS</scp>‐<scp>HF</scp> trial
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the <span>FINEARTS</span>‐<span>HF</span> trial Open
Aims Chronic obstructive pulmonary disease (COPD) is associated with worse outcomes in heart failure (HF) with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). A post hoc analysis of TOPCAT suggested that the effectiveness of …
View article: Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the <scp>FINEARTS</scp>‐<scp>HF</scp> trial
Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the <span>FINEARTS</span>‐<span>HF</span> trial Open
Aims The efficacy and safety of the non‐steroidal mineralocorticoid receptor antagonist, finerenone, have not been examined in patients without diabetes. We examined the efficacy and safety of finerenone, compared with placebo, according t…
View article: Temporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk Score
Temporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk Score Open
Background Heart failure (HF) and frailty often coexist. However, it is unknown how the interplay between HF and frailty at HF onset impacts prognosis of frail patients with HF and how this has evolved over time. Methods and Results We ide…
View article: Patient-reported symptoms and admission pathways in stroke mimics versus confirmed stroke or transient ischaemic attack: a cross-sectional observational study
Patient-reported symptoms and admission pathways in stroke mimics versus confirmed stroke or transient ischaemic attack: a cross-sectional observational study Open
Objectives To determine patient-reported symptoms and clinical factors associated with mimics and differences in health-seeking behaviour versus stroke. Design This is a post-hoc analysis of a cross-sectional survey of interviews on patien…
View article: Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial
Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial Open
Background and Aims An expansion of fat mass is an integral feature of patients with heart failure and preserved ejection fraction (HFpEF). While body mass index (BMI) is the most common anthropometric measure, a measure of central adiposi…
View article: Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction
Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction Open
In patients with HF with mildly reduced/preserved ejection fraction, the beneficial effects of finerenone on clinical events and symptoms were consistent, irrespective of BMI at baseline, possibly with a greater effect on the primary outco…
View article: Effects of sacubitril/valsartan according to background beta‐blocker therapy in patients with heart failure and reduced ejection fraction: Insights from <scp>PARADIGM</scp>‐<scp>HF</scp>
Effects of sacubitril/valsartan according to background beta‐blocker therapy in patients with heart failure and reduced ejection fraction: Insights from <span>PARADIGM</span>‐<span>HF</span> Open
Aims Beta‐blockers may inhibit neprilysin activity and conversely, neprilysin inhibition may have a sympatho‐inhibitory action. Consequently, sacubitril/valsartan may have a greater effect in patients not receiving a beta‐blocker compared …
View article: Long‐term risk of heart failure in patients with postoperative atrial fibrillation following non‐cardiac surgery: Insights from a nationwide cohort
Long‐term risk of heart failure in patients with postoperative atrial fibrillation following non‐cardiac surgery: Insights from a nationwide cohort Open
Aims Atrial fibrillation (AF) is associated with heart failure (HF). However, it is unclear if postoperative AF (POAF) following non‐cardiac surgery differs from non‐surgical AF in terms of the risk of HF. We compared the long‐term rate of…
View article: Blood Flow Restriction Training and Its Use in Rehabilitation After Anterior Cruciate Ligament Reconstruction: A Systematic Review and Meta-Analysis
Blood Flow Restriction Training and Its Use in Rehabilitation After Anterior Cruciate Ligament Reconstruction: A Systematic Review and Meta-Analysis Open
Background/Objectives: Anterior cruciate ligament (ACL) reconstruction (ACLR) is often followed by significant muscle atrophy and subsequent loss of strength. Blood flow restriction training (BFRT) has recently emerged as a potential mode …
View article: Influence of prior heart valve intervention on treatment and disease trajectory after diagnosis of heart failure with reduced ejection fraction
Influence of prior heart valve intervention on treatment and disease trajectory after diagnosis of heart failure with reduced ejection fraction Open
Background and aim Among patients with heart failure with reduced ejection fraction (HFrEF), knowledge is scarce on whether patients with prior valvular heart disease (VHD) intervention are distinct regarding clinical characteristics, trea…
View article: Bacteremia after transcatheter aortic valve implantation: a nationwide cohort study
Bacteremia after transcatheter aortic valve implantation: a nationwide cohort study Open
Background Bacteremia and infective endocarditis (IE) are rare but severe complications to transcatheter aortic valve implantation (TAVI). However, data on early bacteremia and microbiological etiological profile are scarce. Purpose The st…
View article: Dapagliflozin versus empagliflozin and major adverse cardiovascular events in type 2 diabetes: a nationwide cohort study
Dapagliflozin versus empagliflozin and major adverse cardiovascular events in type 2 diabetes: a nationwide cohort study Open
Background Large randomized clinical trials have shown that sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart failure, chronic kidney disease, or type 2 …
View article: Endometriosis and long-term cardiovascular risk: a nationwide Danish study
Endometriosis and long-term cardiovascular risk: a nationwide Danish study Open
Background and Aims Endometriosis, a systemic gynaecological disease affecting 10% of women in reproductive age, shares pathophysiological characteristics with cardiovascular disease. However, data on the relationship between endometriosis…